Safety of Tourniquet Use in Total Knee Arthroplasty in Patients With Radiographic Evidence of Vascular Calcifications

Steven M. Koehler, MD, Adam Fields, BA, Naudereh Noori, BS, Mitchell Weiser, MD, Calin S. Moucha, MD, and Michael J. Bronson, MD

Abstract

Tourniquets are often used in total knee arthroplasty (TKA) to improve visualization of structures, shorten operative time, reduce intraoperative bleeding, and improve cementing technique. Despite these advantages, controversy remains regarding the safety of tourniquet use. Tourniquets have been associated with nerve palsies, vascular injury, and muscle damage. Some have hypothesized they may also cause deep vein thrombosis. Last, increased incidence of postoperative wound complications has been reported with use of tourniquets.

We conducted a retrospective cohort study to determine whether tourniquet use in TKA in patients with preexisting radiographic evidence of vascular disease increases the risk for wound complications or venous thromboembolism (VTE). Patients (N = 373) were placed in 2 groups: One had no preoperative radiographic evidence of knee arterial calcification (n = 285), and the other had arterial calcifications (n = 88). Overall, arterial calcification did not increase the risk for wound complication or VTE (P > .05). Furthermore, location of arterial calcification did not affect risk for wound complication or VTE. There were no arterial injuries. Diabetes, hypertension, prior VTE, coronary artery disease, and male sex were linked to higher wound complication rates (P < .05).

Patients who have preoperative radiographic evidence of arterial calcification can safely undergo tourniquet-assisted TKA.

ourniquets are often used in total knee arthroplasty (TKA) to improve visualization of structures, shorten operative time, reduce intraoperative bleeding, and improve cementing technique. Despite these advantages, controversy remains regarding the safety of tourniquet use. Tourniquets have been associated with nerve palsies, vascular injury, and muscle damage.¹⁻⁵ Some have hypothesized they may cause venous stasis or direct endothelial damage that may develop into deep vein thrombosis (DVT). Abdel-Salam and Eyres⁶ found an increased incidence of postoperative wound complications and DVTs associated with tourniquet use.

Moreover, investigators have analyzed the role of tourniquets in populations at high risk for wound complications. DeLaurentis and colleagues⁷ performed a prospective and retrospective analysis of 1182 TKA patients, 24 (2%) of whom had preexisting peripheral vascular disease (PVD), defined as a history of arterial insufficiency, absent dorsalis pedis and/ or absent posterior tibial pulsations, and arterial calcifications. A tourniquet was used in each case. Arterial complications occurred in 6 of the 24 patients with PVD. As expected, the authors found that a history of intermittent claudication, pain at rest, and arterial ulcers resulted in a high risk for vascular complications. Further studies have supported this finding and expanded the list of predisposing factors to include previous vascular surgery and absent and asymmetric pedal pulsations.⁷⁻¹¹ Of particular concern to total joint arthroplasty surgeons was the finding by DeLaurentis and colleagues⁷ that patients with radiographic evidence of calcification of the distal superficial femoral artery and/or popliteal artery were at risk for arterial complications. This finding is also supported by other studies.^{8,11} In TKA, damage to arterial structures proximal to the surgical field could manifest as impaired postoperative wound healing or an ischemic limb. Wound healing depends on adequate blood flow to the healing tissue, and any damage to arterial or venous structures can theoretically compromise this process.

Added to vascular/wound complications as concerning complications in orthopedic surgery is venous thromboembolism (VTE). The role of tourniquets in the formation of VTEs is controversial. A tourniquet has the potential to increase the risk for DVT because of the stasis of venous blood in the lower limb or possible damage to calcified blood vessels. Callam and colleagues¹² studied the connection between artery disease and chronic leg ulcers and found that half the patients diagnosed with peripheral artery disease also had stigmata of chronic venous insufficiency. Therefore, the entities can occur

Authors' Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article.



Figure. Preoperative radiographs show (A) no calcification of knee, (B) calcification of proximal popliteal artery and distal popliteal artery, (C) calcification of only proximal popliteal artery, and (D) calcification of only distal popliteal artery.

in tandem, and surgeons should keep this in mind.

Here we report on a study we conducted to determine whether tourniquet use in TKA in patients with preexisting radiographic evidence of vascular disease increases the risk for wound complications or VTE.

Patients and Methods

We retrospectively reviewed 461 consecutive primary TKAs (373 patients) performed between January 2007 and June 2012 by 2 attending orthopedic surgeons specializing in adult reconstruction. Medical records and operative reports of 583 patients were examined after receiving institutional review board approval. Of these patients, 373 (64%) had a minimum of 12-month follow-up data available. Twelve months was deemed long enough to discover wound complications or DVTs secondary to the index procedure. Most of these outcomes manifest within the first 3 months after surgery and certainly by 12 months. Follow-up longer than 12 months may become a confounder, as wound complications outside the acute to subacute postoperative window could be related to patients' underlying PVD and not directly to tourniquet use during sur-

gery. Patient demographics and comorbidities were recorded. Comorbidities were obtained from preoperative medical evaluations and surgeons' preoperative evaluations. All patients had preoperative palpable dorsalis pedis and posterior tibialis arterial pulses. No patient required preoperative vascular studies based on preoperative examination or comorbidities. No patient had prior vascular bypass surgery or stenting.

TKA was performed in a nonlaminar flow, positivepressure, high-efficiency particulate air-filtered room with sterile toga/surgical helmet systems. For all patients, a pneumatic thigh tourniquet was applied, and the patient was prepared and draped. After limb exsanguination using a rubber bandage, the limb was elevated and the tourniquet inflated to a pressure of 250 to 300 mm Hg. The tourniquet was released either just before closure or immediately after closure in all cases; it was always let down before placement of final bandages.

Prophylactic chemical anticoagulation consisting of warfarin, aspirin, or enoxaparin was used in all patients and continued for 4 to 6 weeks after surgery. All patients received mechanical DVT prophylaxis with sequential compression devices, and all were mobilized out of bed beginning either the day of surgery or the next day. All patients received perioperative intravenous antibiotics, with the preoperative dose given before tourniquet inflation and the last postoperative dose stopped within 24 hours of surgery.

All patients who had primary TKA underwent preoperative medical evaluation and optimization. The patient's hospital course was monitored closely, and complications noted by the orthopedic team were documented. Follow-up documentation was retrospectively reviewed for evidence of wound complications or VTE. Wound complications were defined as cellulitis, delayed wound healing, wound dehiscence, and/or periprosthetic joint infection. In the case of VTE, physical examination findings were not sufficient for inclusion. Venous duplex ultrasonography demonstrating the clot was reviewed before inclusion.

Preoperative radiographs were examined for arterial calcification (**Figure**). We refer to calcification seen above the knee joint as proximal calcification and to calcification observed below the joint as distal calcification. Patients exhibited calcification proximally only, distally only, or both proximally and distally. The 373 patients were placed into 2 groups based on whether they had preoperative arterial calcification on plain radiography of the knee. One group (285 patients with no radiographic evidence of preoperative knee arterial calcification) underwent 365 TKAs, and the other group (88 patients with radiographic evidence of preoperative knee arterial calcification) underwent 96 TKAs.

A sample size calculation was performed to determine how many patients were needed in each group with 80% power and an α of 0.05. With an estimated difference in VTE/wound complication rate between the calcification and no-calcification groups of 12%, we needed to review 316 TKAs total. This 12% difference was based on study findings of a 25% complication rate in PVD patients who underwent tourniquet-assisted TKA, and the rate of VTE/wound complication after TKA in patients overall, which can be up to 12%.^{7,13,14} We exceeded minimal enrollment and had 461 TKAs. Descriptive statistics were reported, with means and ranges provided where appropriate. Independent t test was used to evaluate the differences in continuous data (age) between the groups. Univariate analysis (using Pearson χ^2 and Fisher exact tests) and multivariate logistic regression analysis were used to evaluate the effects of categorical variables (sex, comorbidity, calcification [presence, absence], and location of calcification [proximal only, distal only, both]) on wound complication and VTE rates. All tests were 2-tailed and performed with a type I error rate of 0.05. Data analysis was performed with SPSS Version 19.0 (SPSS).

Results

Patient characteristics are summarized in **Table 1**. Of the 373 patients, 285 lacked calcification, and 88 had calcification. Mean age was 67.73 years (range, 24-92 years) for all patients, 65.99 years (range, 24-89 years) for the no-calcification group, and 74.32 years (range, 54-92 years) for the calcification group; the calcification group demonstrated a trend toward older age, but the difference was not significantly different (P = .07). Of the 373 patients, 156 (41.82%) were male: 110 in the no-calcification group (38.60%) and 46 in the calcification group (52.27%); sex was significantly (P = .002) different between groups, with more males in the calcification group.

Data on total preoperative comorbidities are summarized in **Table 2**. Hypertension, hyperlipidemia, diabetes, and coronary

artery disease (CAD) were the most common comorbidities, and they were all significantly ($P \le .05$) increased in the calcification group.

No patients had reported arterial complications, such as arterial bleeding, aneurysm, intimal tears, or loss of distal pulses. Wound complication after TKA was detected in 3.04% of all cases (**Table 3**). Rate of DVT after TKA was 2.60% of all cases, and rate of pulmonary embolism after TKA was 2.17% of all cases. Of the 96 TKAs with preoperative radiographic evidence of calcification, 47 (48.96%) had proximal calcification only, 11 (11.46%) had distal calcification only, and 38 (39.58%) had both proximal and distal calcification (**Table 4**). There was no significant difference between the rate of wound complication or VTE based on location of vascular calcification.

Univariate analysis demonstrated that presence of arterial knee calcification did not increase the risk for postoperative wound complication (odds ratio [OR], 1.04; 95% confidence interval [CI], 0.28-3.80; P > .05) (Table 5). Location of arterial knee calcification also did not increase the risk for postoperative wound complication. In addition, univariate analysis demonstrated that presence of arterial knee calcification did not increase the risk for postoperative VTE (OR, 1.20; 95% CI, 0.43-3.36; P > .05 (Table 6).

Of the 14 wound complications, the most common infections were cellulitis (5/14 cases; 35.71%) and infected hardware that required component revision (5/14 cases; 35.71%).

Table 1. Demographics

	Group					
Demographic	Total	No Calcification	Calcification	P		
Procedures (patients), n	461 (373)	365 (285)	96 (88)	_		
Mean (range) age, y	67.73 (24-92)	65.99 (24-89)	74.32 (54-92)	.07		
Male, n (%)	156 (41.82)	110 (38.60)	46 (52.27)	.002		

Table 2. Comorbidities

			Group				
	Total (N = 461)		No Calcifica	tion (n = 365)	Calcification (n = 96)		-
Comorbidity	n	%	n	%	n	%	Р
Hypertension	322	69.85	241	66.03	81	84.38	<.001
Hyperlipidemia	143	31.02	105	28.77	38	31.25	.05
Diabetes	86	18.66	56	15.34	30	31.25	.001
Coronary artery disease	73	15.84	45	12.33	28	29.17	<.001
Other cardiac disease	55	11.93	39	10.68	16	16.67	.26
Congestive heart failure	9	1.95	6	1.64	3	3.13	_
Arrhythmia	26	5.64	19	5.21	7	7.29	_
Valve disease	20	4.34	14	3.84	6	6.25	—
Prior venous thromboembolism	25	5.42	19	5.21	6	6.25	.62
Gout	16	3.47	13	3.56	3	3.13	>.99

Mean time from TKA to infection was 137.93 days (range, 5-783 days). The most common organism grown in culture from the wound was Staphylococcus (5/14 cases; 35.71%).

Additional univariate statistical analysis revealed that presence of diabetes, hypertension, prior VTE, CAD, and male sex was linked to higher incidence of wound complication (P < .05) (Table 5). When multivariate analysis was performed, hypertension, prior VTE, and male sex remained significant (P < .05) (Table 5).

Discussion

TKA is a safe and effective procedure used to treat osteoarthritis of the knee and improve patients' quality of life.¹⁵ About 700,000 TKAs are performed annually in the United States.¹⁶ Because of improvements in preventive medicine and medical technology, life expectancy is increasing, and TKAs are now being performed in higher numbers and in an older patient population. Over the next few decades, these developments will lead to more postoperative complications. It is projected that, by 2030, the need for TKAs in the United States will increase by 673% to 3.48 million.¹⁷ Postoperative complications are rare but unfortunately often lead to poor outcomes or even mortality.¹⁸ To help minimize the number of postoperative complications, we must understand the safety of tourniquet use in TKA. Other investigators have concluded that tourniquet use is unsafe in patients with preoperative vascular calcifications on plain radiographs.^{7,8,11} The present study, designed to elucidate whether preoperative evidence of knee arterial calcification may predispose TKA patients to postoperative wound complication or VTE, had some important findings.

In our study, wound complication and VTE occurred in a considerable number of patients after TKA. Despite exceeding the number of patients calculated by the power analysis, our population may have been inadequate to fully detect statistical significance. Thus, our conclusion of failing to reject the null hypothesis may have been because of sample size, a type II error. We found that, after primary TKA, 3.04% of patients developed wound complications and 4.77% VTE. According to the literature, the incidence of infection after primary TKA is between 0.5% and 12%, and that of VTE reported within 3 months after TKA is 1.3% to 10%.^{13,14} Although we had 100% VTE prophylaxis, meeting the standard of care, VTE after

Table 3. Complications After Total Knee Arthroplasty

	Total (N = 461)		No Calcifica	tion (n = 365)	Calcification (n = 96)		-
Complication	n	%	n	%	n	%	Р
Wound complications							
Cellulitis	5	1.08	4	1.10	1	1.04	_
Infected hardware	5	1.08	4	1.10	1	1.04	_
Dehiscence	2	0.43	2	0.55	0	0.00	_
Delayed wound healing	2	0.43	1	0.27	1	1.04	_
Total	14	3.04	11	3.01	3	3.13	>.99
Venous thromboembolism		•••••	••••••••••	••••••		•••••	• •••••
Pulmonary embolism	10	2.17	7	1.92	3	3.13	_
Deep vein thrombosis	12	2.60	10	2.74	2	2.08	_
Total	22	4.77	17	4.66	5	5.21	.79

Table 4. Complications After Total Knee Arthroplasty by Location of Calcification (n = 96)

Complication	Location of Calcification							
	Proximal (n = 47; 48.96%)		Distal (n = 11; 11.46%)		Both (n = 38; 39.58%)		-	
	n	%	n	%	n	%	Р	
Wound complications								
Cellulitis	1	2.13	0	0.00	0	0.00	_	
Delayed wound healing	1	2.13	0	0.00	0	0.00	_	
Infected hardware	0	0.00	0	0.00	1	2.56	_	
Total	2	4.26	0	0.00	1	2.56	.75	
Venous thromboembolism								
Deep vein thrombosis	2	4.26	0	0.00	0	0.00	_	
Pulmonary embolism	1	2.13	1	9.09	1	2.56	_	
Total	3	6.38	1	9.09	1	2.56	.98	

Table 5. Univariate and Multivariate Analyses for Risk Factors for Postoperative Wound Complication **Among Cohort**

		Wound Co				
	Yes (n = 14)		No (n	= 447)		
Variable	n	%	n	%	OR (95% CI)	Р
Demographics						
Sex						
Male	9	64	147	33	3.67 (1.21-11.16)	.02ª
Female	5	36	300	67		
Age						•••••
<70 y	9	64	208	47	2.07 (0.68-6.23)	.28 ^b
≥70 y	5	36	239	53		
Comorbidities						
Hypertension						
Yes	14	100	308	69	No data	.008ª
No	0	0	139	31		
Diabetes		•••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••
Yes	6	43	80	18	3.44 (1.16-10.19)	.03 ^b
No	8	57	367	82		
Hyperlipidemia		•••••	••••••	•••••	•••••••••••••••••••••••••••••••••••••••	•••••
Yes	5	36	138	31	1.20 (0.41-3.78)	.77 ^b
No	9	64	309	69		
Coronomi ortomi diagogo		•••••	••••••	•••••	•••••••••••••••••••••••••••••••••••••••	•••••
Coronary artery disease	5	36	68	15	3 10 (1 00-9 52)	05 ^b
No	9	64	379	85	0.10 (1.00 0.02)	.00
		•••••			•••••••••••••••••••••••••••••••••••••••	•••••
Uther cardiac	0	14	16	10	1 45 (0 22 6 60)	65b
No	12	86	401	90	1.45 (0.52-0.09)	.00
	·····				•••••••••••••••••••••••••••••••••••••••	•••••
Prior venous thromboembolism	0	01	00	5	5 00 (1 07 00 05)	048
No		79	425	95	5.25 (1.57-20.25)	.04-
-						•••••
Gout		7	45	0		10h
Yes	13	((15	3	2.22 (0.27-18.05)	.405
	10		402	51		
Calcification						
Calcification	-					0.01
Yes No	3 11	21 79	93 354	21 79	1.04 (0.28-3.80)	>.99⁵
Above joint only		•••••	••••••	•••••	•••••••••••••••••••••••••••••••••••••••	•••••
Yes	2	14	45	10	1.45 (0.32-6.86)	.64 ^b
No	12	86	402	90		
Rolow icint only		•••••	••••••	••••••		
Yes	0	0	11	3	No data	> 99b
No	14	100	436	97		2.00
Dath		••••••	••••••	••••••	•••••••••••••••••••••••••••••••••••••••	•••••
	1	7	37	Q	0.85 (0.12-6.70)	< QQb
No	13	93	410	92	0.00 (0.12-0.70)	2.33
				<u>.</u>		

Abbreviations: CI, confidence interval; OR, odds ratio. "Significant in multivariate analysis and Fisher exact test. "Significant in Fisher exact test only.

TKA remains a postoperative complication.¹⁹ This study also found that a considerable percentage of primary TKA patients (23.59%) had preoperative calcification of the knee arteries.

To our knowledge, this study was the first to quantify the incidence of knee arterial calcification in patients who underwent TKA.

Table 6. Univariate Analysis for Risk Factors for Postoperative Venous Thromboembolism Among Cohort

Versible No (n = 440) Univariate Analysis: OR (65% CI) P Demographics - - - - P Ser, Maie 7 3.3 14.4 67 291 66 0.98 (0.36-2.47) >.99 Fernale 14 67 291 66 0.98 (0.36-2.47) >.99 Age - 270 y 10 48 207 47 1.02 (0.43-2.46) >.99 270 y 10 48 207 47 1.02 (0.43-2.46) >.99 Comorbidities - <th></th> <th></th> <th>Venous Thro</th> <th></th> <th colspan="2"></th>			Venous Thro					
Variable n % n % OP (95% C1) P Demographics Sex		Yes (n = 21)		No (n	= 440)	Univariate Analysis		
Demographics Sex Name Sec	Variable	n	%	n	%	OR (95% CI)	Р	
Sex Melle 7 33 149 34 0.98 (0.39-2.47) >.99 Fernale 14 67 291 66	Demographics							
Male 7 33 149 34 0.98 $(0.39-2.47)$ >.99 Fernale 14 67 201 66	Sex							
Female 14 67 291 66 Age $<$ 70 y 10 48 207 47 1.02 (0.43:2.46) >.99 270 y 11 62 233 53	Male	7	33	149	34	0.98 (0.39-2.47)	>.99	
Age	Female	14	67	291	66			
-70 y 10 48 207 47 1.02 (0.43-2.46) >99 270 y 11 52 233 53	Age		• • • • • • • • • • • • • • • • • • • •				•••••	
z70 y 11 52 233 53 Comorbidities Hypertension Yes 16 76 306 70 1.41 (0.50-3.90) .63* No 5 24 134 30 Diabetes yes 3 14 83 19 0.72 (0.21-2.49) .78* No 18 86 357 81 Yes 5 24 138 31 0.68 (0.25-1.90) .63* No 16 76 302 69 Ves 5 24 138 31 0.68 (0.25-3.07) >99* No 18 76 43 10 2.89 (1.01-8.26) .06* No 18 76 43 10 2.89 (1.01-8.26) .06* No 18 76 418 9	<70 y	10	48	207	47	1.02 (0.43-2.46)	>.99	
Comorbidities Hypertension Yes 16 76 306 70 1.41 (0.50-3.90) 6.3° No 5 24 134 30 78° Diabetes """"""""""""""""""""""""""""""""""	≥70 y	11	52	233	53			
Hypertension Yes 16 76 306 70 1.41 (0.50-3.90) 6.54 No 5 24 134 30 634 Diabetes Yes 3 14 83 19 0.72 (0.21-2.49) .78 ^o No 18 86 357 81 78 ^o 78 ^o No 18 86 357 81 68 ^o 69 ^o Order Correlation 76 ^o 302 69 69 ^o 63 ^a No 16 76 302 69 69 ^o 59 ^a No 18 86 370 84 60 ^o 59 ^o Other cardiac Yes 5 24 43 10 2.89 (1.01-8.26) .06 ^o No 16 76 397 90 .06 ^o .06 ^o No 16 76 397 90 .06 ^o .06 ^o No 18 76 418 9 .06 ^o	Comorbidities							
Yes 16 76 20 7.0 1.41 (0.50.3.90) 6.3° No 5 24 134 30	Hypertension							
No 5 24 134 30 Diabetes Yes 3 14 83 19 $0.72 (0.21-2.49)$.78° No 18 86 357 81 .78° Pyes 5 24 138 31 $0.68 (0.25-1.90)$.63° No 16 76 302 69	Yes	16	76	306	70	1.41 (0.50-3.90)	.63ª	
Diabetes Ves 3 14 83 19 0.72 (0.21-2.49) .78* No 18 86 357 81	No	5	24	134	30			
Yes3148319 $0.72 (0.21:2.49)$ 7.8° No188635781 7.8° 7.8° Hyperlipidemia*********************************	Diabetes		••••••				•••••	
No 18 86 357 81 Hyperlipidemia Yes 5 24 138 31 0.68 (0.25-1.90) .63° No 16 76 302 69	Yes	3	14	83	19	0.72 (0.21-2.49)	.78ª	
Hyperlipidemia Yes 5 24 138 31 0.68 (0.25-1.90) 63^n No 16 76 302 69 69 63^n Coronary artery disease 7 16 0.88 (0.25-1.90) 63^n Yes 3 14 70 16 0.88 (0.25-3.07) >.99^n No 18 86 370 84	No	18	86	357	81			
Yes524138310.68 (0.25-1.90).63"No167630269	Hyperlipidemia		••••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No 16 76 302 69 Coronary artery disease Yes 3 14 70 16 0.88 (0.25-3.07) >.99* No 18 86 370 84	Yes	5	24	138	31	0.68 (0.25-1.90)	.63ª	
Coronary artery disease Yes 3 14 70 16 0.88 (0.25-3.07) >.99* No 18 86 370 84	No	16	76	302	69			
Yes 3 14 70 16 0.88 (0.25-3.07) >99 ^a No 18 86 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 370 84 36 36 36 36 36 36 36 36 36 370 84 36	Coronary artery disease	••••••	•••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No 18 86 370 84 Other cardiac Yes 5 24 43 10 2.89 (1.01-8.26) .06 ^a No 16 76 397 90 .06 ^a Prior venous thromboembolism 76 397 90 .06 ^a Yes 3 14 22 5 3.17 (0.87-11.57) .10 ^a No 18 76 418 9 .06 ^a .06 ^a Gout Yes 2 10 14 3 3.20 (0.68-15.11) .16 ^a No 19 90 426 97 .00 ^a .06 ^a Calcification Tess 24 91 21 1.20 (0.43-3.36) .78 ^a No 16 76 349 79 .00 ^a .06 ^a Above joint only Yes 3 14 44 10 1.50 (0.43-5.30) .46 ^a No 18 86 396 90 .150 (0.26-17.63) </td <td>Yes</td> <td>3</td> <td>14</td> <td>70</td> <td>16</td> <td>0.88 (0.25-3.07)</td> <td>>.99ª</td>	Yes	3	14	70	16	0.88 (0.25-3.07)	>.99ª	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	No	18	86	370	84	, , , , , , , , , , , , , , , , , , ,		
Yes52443102.89 (1.01-8.26).06°No167639790Prior venous thromboembolismYes314225 $3.17 (0.87-11.57)$.10°No187641899GoutYes210143 $3.20 (0.68-15.11)$.16°No199042697.CalcificationYes52491211.20 (0.43-3.36).78°No167634979.Above joint only Yes31444101.50 (0.43-5.30).46°No188639690Below joint only Yes151022.15 (0.26-17.63).41°No209543098Both Yes153780.55 (0.07-4.17)>.99°No209540392	Other cardiac	••••••	••••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No167639790Prior venous thromboembolism Yes314225 $3.17 (0.87 \cdot 11.57)$ $.10^{\circ}$ No187641899Gout Yes210143 $3.20 (0.68 \cdot 15.11)$ $.16^{\circ}$ No19904269716^{\circ} 16° CalcificationYes5249121 $1.20 (0.43 \cdot 3.36)$ $.78^{\circ}$ No167634979 $.78^{\circ}$ $.78^{\circ}$ Above joint only Yes3144410 $1.50 (0.43 \cdot 5.30)$ $.46^{\circ}$ No188639690 $.46^{\circ}$ $.41^{\circ}$ No102 $2.15 (0.26 \cdot 17.63)$ $.41^{\circ}$ No209543098 $.41^{\circ}$ Both 	Yes	5	24	43	10	2.89 (1.01-8.26)	.06ª	
$\begin{array}{c cccccccccccc} Prior venous thromboembolism & & & & & & & & & & & & & & & & & & &$	No	16	76	397	90			
Yes314225 $3.17 (0.87-11.57)$ $.10^a$ No18764189Gout210143 $3.20 (0.68-15.11)$ $.16^a$ Yes210143 $3.20 (0.68-15.11)$ $.16^a$ No199042697 21 $1.20 (0.43-3.36)$ $.78^a$ CalcificationYes5249121 $1.20 (0.43-3.36)$ $.78^a$ No167634979 $.78^a$ Above joint onlyYes3144410 $1.50 (0.43-5.30)$ $.46^a$ No188639690 $.46^a$ Below joint onlyYes15102 $2.15 (0.26-17.63)$ $.41^a$ No209543098 $.45 (0.07-4.17)$ $>.99^a$ BothYes15378 $0.55 (0.07-4.17)$ $>.99^a$ No209540392 $.41 (0.3) (0.43-5.30) (0.43$	Prior venous thromboembolism	••••••	••••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No18764189Gout Yes210143 $3.20 (0.68-15.11)$ $.16^a$ No199042697CalcificationYes5249121 $1.20 (0.43-3.36)$ $.78^a$ No167634979Above joint only Yes3144410 $1.50 (0.43-5.30)$ $.46^a$ No188639690Below joint only Yes15102 $2.15 (0.26-17.63)$ $.41^a$ No209543098Both Yes15378 $0.55 (0.07-4.17)$ >.99^aNo209540392 92 92	Yes	3	14	22	5	3.17 (0.87-11.57)	.10ª	
Gout Yes210143 $3.20 (0.68-15.11)$ $.16^a$ No199042697CalcificationYes5249121 $1.20 (0.43-3.36)$ $.78^a$ No167634979 $.78^a$ Above joint only Yes3144410 $1.50 (0.43-5.30)$ $.46^a$ No188639690 $.46^a$ Below joint only Yes15102 $2.15 (0.26-17.63)$ $.41^a$ No209543098 $.403$ 92	No	18	76	418	9	, , , , , , , , , , , , , , , , , , ,		
Yes 2 10 14 3 3.20 (0.68-15.11) .16 ^a No 19 90 426 97 Calcification	Gout		•••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No 19 90 426 97 Calcification <th<< td=""><td>Yes</td><td>2</td><td>10</td><td>14</td><td>3</td><td>3.20 (0.68-15.11)</td><td>.16ª</td></th<<>	Yes	2	10	14	3	3.20 (0.68-15.11)	.16ª	
Calcification Yes 5 24 91 21 1.20 (0.43-3.36) .78ª No 16 76 349 79	No	19	90	426	97	, , , , , , , , , , , , , , , , , , ,		
Calcification Yes 5 24 91 21 1.20 (0.43-3.36) .78ª No 16 76 349 79 .78ª .78ª Above joint only	Calcification							
Yes52491211.20 (0.43-3.36).78°No167634979Above joint only Yes31444101.50 (0.43-5.30).46°No188639690	Calcification							
No 16 76 349 79 Above joint only	Yes	5	24	91	21	1.20 (0.43-3.36)	.78ª	
Above joint only Yes 3 14 44 10 1.50 (0.43-5.30) .46ª No 18 86 396 90	No	16	76	349	79			
Yes 3 14 44 10 1.50 (0.43-5.30) .46 ^a No 18 86 396 90 90 Below joint only Yes 1 5 10 2 2.15 (0.26-17.63) .41 ^a No 20 95 430 98 98 Both Yes 1 5 37 8 0.55 (0.07-4.17) >.99 ^a No 20 95 403 92	Above joint only	••••••	••••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••••••••••••••••••••••••••••••••••••	•••••	
No 18 86 396 90 Below joint only Yes 1 5 10 2 2.15 (0.26-17.63) .41ª No 20 95 430 98 98 Both Yes 1 5 37 8 0.55 (0.07-4.17) >.99ª No 20 95 403 92 39 39 30	Yes	3	14	44	10	1.50 (0.43-5.30)	.46ª	
Below joint only Yes 1 5 10 2 2.15 (0.26-17.63) .41a No 20 95 430 98	No	18	86	396	90			
Yes 1 5 10 2 2.15 (0.26-17.63) .41a No 20 95 430 98 .41a Both	Below joint only	•••••	••••••	•••••	•••••	•••••••••••••••••••••••••••••••••••••••		
No 20 95 430 98 Both	Yes	1	5	10	2	2.15 (0.26-17.63)	.41ª	
Both Yes 1 5 37 8 0.55 (0.07-4.17) >.99 ^a No 20 95 403 92	No	20	95	430	98			
Yes 1 5 37 8 0.55 (0.07-4.17) >.99a No 20 95 403 92	Both		••••••	•••••	•••••	•••••••••••••••••••••••••••••••••••••••	•••••	
No 20 95 403 92	Yes	1	5	37	8	0.55 (0.07-4.17)	>.99ª	
	No	20	95	403	92			

Abbreviations: CI, confidence interval; OR, odds ratio. ^aSignificant in Fisher exact test. Preoperative calcification of the knee arteries in patients who underwent TKA did not increase the risk for wound complication, VTE, or arterial damage. These calcifications, however, do pose an increased systemic vascular risk.²⁰ Calcification of the vascular wall predicts increased cardiovascular risk, independent of classical cardiovascular risk factors.^{3,18,21-24} Clinically, patients who have both diabetes and calcifications are at significant excess risk for total mortality, stroke mortality, and cardiovascular mortality, compared with patients with diabetes but without such calcifications. They also had a significantly higher incidence of coronary heart disease events, stroke events, and lower extremity amputations.^{25,26}

All our patients underwent tourniquet-assisted TKA. Although previous studies have indicated that tourniquet use may increase arterial complications and wound complications or even limb loss in patients with calcified arteries, we did not find this link.^{7,27} Our population had no reported arterial complications related to tourniquet use. Other, smaller studies have had similar findings. Vandenbussche and colleagues²⁸ prospectively studied 80 TKA cases randomized to tourniquet use or no tourniquet use and found no postoperative nerve palsies, wound infections, wound healing problems, or hematomas. Our study is also in accord with studies that have reported tourniquet use did not increase risk for DVT.²⁹ Therefore, unlike earlier data, our data demonstrated that tourniquet use in patients with knee arterial calcification was safe.^{7,27,30,31}

Patients with calcification were more likely to have the medical comorbidities of hypertension, diabetes, hyperlipidemia, and CAD. All these comorbidities are linked to the development of arterial calcification, or atherosclerotic occlusive disease.^{32,33} As life expectancy and the need for TKA increase, it is likely that a larger percentage of TKA patients will have preoperative radiographic evidence of knee arterial calcification. Although current dogma is that tourniquet-assisted TKA is contraindicated for patients with preoperative radiographic evidence of femoral-popliteal calcification, our study results showed that this calcification should not affect preoperative TKA planning for these patients.

We divided our patients into 3 categories: those with proximal calcification (above the joint line), those with distal calcification (below the joint line), and those with both proximal and distal calcification. Location of arterial calcification did not have an effect on their rates of postoperative wound complication or VTE. We hypothesized that patients with proximal calcification would be at increased risk for direct arterial injury and subsequent wound complication because the tourniquet is placed proximally. Previous research has indicated that arterial occlusion and subsequent wound complication can occur because of low blood flow stemming from tourniquet use.⁷ Further, intraoperative manipulation (flexing) of a knee with calcified vessels causes arterial complications after TKA because these vessels are less elastic than nonatheromatous vessels.³¹ However, we found no such effect. At the same time, having arterial calcification might also be an indication of venous disease in this location,¹² which may be especially important for proximal calcifications. Proximal DVT more likely is a precursor to pulmonary embolic events than distal DVT is.^{31,34} However, we found no difference in VTE rates among the 3 arterial location groups, which is supported by studies that have found that tourniquet use does not increase DVT incidence.^{29,35-40}

Risk for wound complications was higher in male patients and in patients with diabetes, prior VTE, hypertension, or CAD. This finding is important because, with the increasing age of patients who undergo TKA, those with serious medical comorbidities will continue to need and have this surgery.¹⁷ Diabetes may increase the rate of wound complication because patients with diabetes have poor microcirculation, poor collagen synthesis, and reduced wound strength.41 Malinzak and colleagues⁴² demonstrated that, compared with patients without diabetes, those with diabetes had a significantly higher risk for infection after TKA. Prior VTE, specifically DVT, may increase the rate of wound complication because after DVT the deep veins may be damaged and exhibit valvular dysfunction. Labropoulos and colleagues⁴³ showed that DVT history was strongly associated with ulcer nonhealing. Perhaps hypertension has been overlooked as a risk factor for wound complication in TKA. No previous studies have assessed the link between hypertension and wound complications after TKA. However, a study of wound healing after total hip arthroplasty found that, compared with normotensive patients, hypertensive patients had delayed wound healing, putting them at higher risk for infection.44 In addition, we found that patients with CAD were at increased risk for wound complications-an unexpected finding, as CAD traditionally is not a risk factor for infection or poor wound healing. Recently, however, CAD was identified as an independent risk factor for surgical site infections in posterior lumbar-instrumented arthrodesis.45 The etiology of this association is unknown. Also, male patients were at increased risk for wound complication. Male sex has been implicated as an independent risk factor for development of surgical site infections and has been established as an important predisposing factor for periprosthetic joint infections.⁴⁶

It is possible that patients who present with diabetes, VTE, hypertension, or CAD before TKA should have a consultation with a vascular surgeon or should have TKA performed without a tourniquet, but this conclusion cannot be considered definitive without a large prospective randomized trial or possibly registry data. Our data indicate that patients with these comorbidities have higher rates of wound complications irrespective of preoperative radiographic calcifications. On the basis of our study results, however, we certainly recommend that patients with these risk factors have preoperative medical optimization. Orthopedic surgeons should take a thorough history and perform a meticulous physical examination on these patients to look for evidence of PVD. We recommend that, if vascular claudication is elicited in the history, or if there is evidence of peripheral arterial disease-such as hair loss, skin discoloration, dystrophic nail changes, or absent or unequal peripheral pulses-the ankle-brachial index test should be performed. If the index value is less than 0.9, then a preoperative vascular surgery consultation should be obtained.

This study had some weaknesses. First, it was retrospective,

so it is possible that some wound or VTE complications were not reported and thus not found in the paper charts or electronic medical records. Some patients may have had VTE diagnostic scans at other hospitals, and their results may not have been recorded across databases. Moreover, some patients may have seen wound specialists for wound infections or wound healing problems, and these may not have been reported to the orthopedic surgeons. Second, though our patient population was not small, it may not have been of adequate size to fully detect statistical significance. We met our enrollment numbers based on our sample size calculations from an a priori power analysis; however, we still draw conclusions with the possibility of committing a type II error in mind by failing to reject the null hypothesis when in reality a statistically significant difference does exist. Third, none of our consecutive patients carried the preoperative diagnosis of PVD, and none had preoperative vascular surgery. Therefore, though calcifications were noted on radiographs, clinically our patients were asymptomatic with respect to vascular health. Last, the 2 groups were not randomized. All patients underwent tourniquet-assisted TKA.

Conclusion

To our knowledge, this is the largest study to examine the effect of preoperative knee arterial calcification on wound complication and VTE after tourniquet-assisted TKA. Contrary to previously published recommendations, we conclude that TKA can be safely performed with a tourniquet in the presence of preoperative radiographic evidence of such calcification. However, we recommend that patients with diabetes, hypertension, CAD, or prior VTE undergo an appropriate physical examination to elicit any signs or symptoms of vascular disease. If before surgery there is any question of vascular competence, a vascular surgeon should be consulted.

Dr. Koehler is House Staff Surgeon, Mr. Fields and Ms. Noori are Medical Students, Dr. Weiser is House Staff Surgeon, Dr. Moucha is Assistant Professor of Orthopaedic Surgery, and Dr. Bronson is Associate Professor of Orthopaedic Surgery, Leni and Peter W. May Department of Orthopaedic Surgery, Mount Sinai Medical Center, New York, New York.

Address correspondence to: Calin S. Moucha, MD, Leni and Peter W. May Department of Orthopaedic Surgery, Mount Sinai Medical Center, 5 E 98th St, 7th Floor, Box 1188, New York, NY 10029 (tel, 212-241-1461; fax, 212-241-9710; email, calin.moucha@mountsinai.org).

Am J Orthop. 2015;44(9):E308-E316. Copyright Frontline Medical Communications Inc. 2015. All rights reserved.

References

- Guanche CA. Tourniquet-induced tibial nerve palsy complicating anterior cruciate ligament reconstruction. *Arthroscopy*. 1995;11(5):620-622.
- Irvine GB, Chan RN. Arterial calcification and tourniquets. *Lancet*. 1986;2(8517):1217.
- Patterson S, Klenerman L. The effect of pneumatic tourniquets on the ultrastructure of skeletal muscle. J Bone Joint Surg Br. 1979;61(2):178-183.
- Rorabeck CH, Kennedy JC. Tourniquet-induced nerve ischemia complicating knee ligament surgery. Am J Sports Med. 1980;8(2):98-102.
- Shenton DW, Spitzer SA, Mulrennan BM. Tourniquet-induced rhabdomyolysis. A case report. J Bone Joint Surg Am. 1990;72(9):1405-1406.
- Abdel-Salam A, Eyres KS. Effects of tourniquet during total knee arthroplasty. A prospective randomised study. J Bone Joint Surg Br. 1995;77(2):250-253.

- DeLaurentis DA, Levitsky KA, Booth RE, et al. Arterial and ischemic aspects of total knee arthroplasty. Am J Surg. 1992;164(3):237-240.
- Holmberg A, Milbrink J, Bergqvist D. Arterial complications and knee arthroplasty. Acta Orthop Scand. 1996;67(1):75-8.
- Hozack WJ, Cole PA, Gardner R, Corces A. Popliteal aneurysm after total knee arthroplasty. Case reports and review of the literature. *J Arthroplasty*. 1990;5(4):301-305.
- Kumar SN, Chapman JA, Rawlins I. Vascular injuries after total knee arthroplasty: a review of the problem with special reference to the possible effects of the tourniquet. *J Arthroplasty*. 1998;13(2):211-216.
- Rush JH, Vidovich JD, Johanson MA. Arterial complications and total knee arthroplasty. The Australian experience. *J Bone Joint Surg Br.* 1987;69(3):400-402.
- Callam MJ, Harper DR, Dale JJ, Ruckley CV. Arterial disease in chronic leg ulceration: an underestimated hazard? Lothian and Forth Valley Leg Ulcer Study. *Br Med J (Clin Res Ed)*. 1987;294(6577):929-931.
- Blom AW, Brown J, Taylor AH, Pattison G, Whitehouse S, Bannister GC. Infection after total knee arthroplasty. *J Bone Joint Surg Br.* 2004;86(5): 688-691.
- Geerts WH, Bergqvist D, Pinco G, et al. Prevention of venous thromboembolism. Chest. 2008;133(6 suppl):381S-453S.
- Pulido L, Parvizi J, Macgibeny M, et al. In hospital complications after total joint arthroplasty. *J Arthroplasty*. 2008;23(6 Suppl 1):139-145.
- Arthritis: data and statistics. Centers for Disease Control and Prevention website. http://www.cdc.gov/arthritis/data_statistics.htm. Updated March 11, 2015. Accessed July 27, 2015.
- Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am.* 2007;89(4):780-785.
- Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. *Clin Orthop Relat Res.* 2008;466(7):1710-1715.
- Warwick D. Prevention of venous thromboembolism in total knee and hip replacement. *Circulation*. 2012;125(17):2151-2155.
- Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. *Vasc Health Risk Manag.* 2009;5(1):185-197.
- Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46(1):158-165.
- Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. *JAMA*. 2000;283(21):2810-2815.
- Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. *Radiology*. 2003;228(3):826-833.
- Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol. 2005;46(5):807-814.
- Lehto S, Niskanen L, Suhonen M, Rönnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol.* 1996;16(8):978-983.
- Niskanen L, Siitonen O, Suhonen M, Uusitupa MI. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. *Diabetes Care*. 1994;17(11):1252-1256.
- Smith DE, McGraw RW, Taylor DC, et al. Arterial complications and total knee arthroplasty. J Am Acad Orthop Surg. 2001;9(4):253-257.
- Vandenbussche E, Duranthon L, Couturier M, Pidhorz L, Augereau B. The effect of tourniquet use in total knee arthroplasty. *Int Orthop.* 2002;26(5): 306-309.
- Fukunda A, Hasegawa M, Kato K, Shi D, Sudo A, Uchida A. Effect of tourniquet application on deep vein thrombosis after total knee thrombosis. *Arch Orthop Trauma Surg.* 2007;127(8):671-675.
- Butt U, Samuel R, Sahu A, Butt IS, Johnson DS, Turner PG. Arterial injury in total knee arthroplasty. J Arthroplasty. 2010;25(8):1311-1318.
- Langkamer VG. Local vascular complications after knee replacement: a review with illustrative case reports. *Knee*. 2001;8(4):259-264.
- Hussein A, Uno K, Wolski K, et al. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol. 2011;57(10): 1220-1225.

- 33. Ouriel K. Peripheral arterial disease. Lancet. 2001;358(9289):1257-1264.
- Monreal M, Rufz J, Olazabal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism. *Chest.* 1992;102(3):677-681.
- Angus PD, Nakielny R, Goodrum DT. The pneumatic tourniquet and deep venous thrombosis. J Bone Joint Surg Br. 1983;65(3):336-339.
- Fahmy NR, Patel DG. Hemostatic changes and postoperative deep-vein thrombosis associated with use of a pneumatic tourniquet. *J Bone Joint Surg Am.* 1981;63(3):461-465.
- Harvey EJ, Leclerc J, Brooks CE, Burke DL. Effect of tourniquet use on blood loss and incidence of deep vein thrombosis in total knee arthroplasty. *J Arthroplasty.* 1997;12(3):291-296.
- Simon MA, Mass DP, Zarins CK, Bidani N, Gudas CJ, Metz CE. The effect of a thigh tourniquet on the incidence of deep venous thrombosis after operations on the fore part of the foot. J Bone Joint Surg Am. 1982;64(2):188-191.
- Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66(2):194-201.
- Wakankar HM, Nicholl JE, Koka R, D'Arcy JC. The tourniquet in total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Br.

1999;81(1):30-33.

- Vince K, Chivas D, Droll K. Wound complications after total knee arthroplasty. J Arthroplasty. 2007;22(4 Suppl 1):39-44.
- Malinzak RA, Ritter MA, Berend ME, Meding JB, Olberding EM, Davis KE. Morbidly obese, diabetic, younger, and unilateral joint arthroplasty patients have elevated total joint arthroplasty infection rates. *J Arthroplasty*. 2009;24(6 Suppl):84-88.
- Labropoulos N, Wang E, Lanier S, Khan SU. Factors associated with poor healing and recurrence of venous ulceration. *Plast Reconstr Surg.* 2011;129(1):179-186.
- Ahmed AA, Mooar PA, Kleiner M, Torg JS, Miyamoto CT. Hypertensive patients show delayed wound healing following total hip arthroplasty. *PLoS One.* 2011;6(8):e23224.
- Koutsoumbelis S, Hughes AP, Girardi FP, et al. Risk factors for postoperative infection following posterior lumbar instrumented arthrodesis. *J Bone Joint Surg Am*. 2001;93(17):1627-1633.
- Poultsides LA, Ma Y, Della Valle AG, Chiu YL, Sculco TP, Memtsoudis SG. In-hospital surgical site infections after primary hip and knee arthroplasty– incidence and risk factors. J Arthroplasty. 2013;28(3):385-389.